Tavapadon is under clinical development by Cerevel Therapeutics Holdings and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tavapadon’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tavapadon Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tavapadon (PF-06649751) is under development for the treatment of Parkinson's disease. The drug candidate is administered orally as a tablet and suspension. It acts by targeting dopamine 1 and dopamine 5 receptor.
Cerevel Therapeutics Holdings overview
Cerevel Therapeutics Holdings (Cerevel Therapeutics) is a biopharmaceutical company. It develops and commercializes medicines for the treatment of central nervous system (CNS) disorders. Cerevel Therapeutics is headquartered in Boston, Massachusetts, United States.
Quick View Tavapadon LOA Data
|Highest Development Stage|